Health Economics›CNS lymphoma›Relapsed or refractory subsequent lines of therapy

Relapsed or refractory subsequent lines of therapy

CNS lymphoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Topotecan monotherapy Variant #01	—	R 18 138	21d	~4.4 mo	~8.5 mo	~11	~R 199 522 PFS proxy · indirect	21
Temozolomide monotherapy Variant #02	—	R 3 434	14d	~4.0 mo	~16.3 mo	~27	~R 92 712 PFS proxy · indirect	10
Rituximab monotherapy Variant #09 Partial	—	—	28d	~5.2 mo	—	~1	—	3
Temsirolimus monotherapy Variant #02 Partial	—	—	28d	~4.8 mo	~23.5 mo	~2	—	2

4 of 4 regimens shown